CLINICAL TRIALS PROFILE FOR BROMOCRIPTINE MESYLATE
✉ Email this page to a colleague
All Clinical Trials for BROMOCRIPTINE MESYLATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00377676 ↗ | Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes | Completed | VeroScience | Phase 3 | 2004-07-01 | Cycloset, a new quick-release oral formulation of bromocriptine mesylate, effectively reduces blood sugar by the proposed mechanism of reversing many of the metabolic alterations associated with insulin resistance and obesity by resetting central (hypothalamic) circadian organization of monoamine neuronal activities. The primary analysis of this study will test the hypothesis that the rate of all-cause severe adverse events for those receiving usual drug therapy for diabetes management plus Cycloset is not greater than that for usual drug therapy plus placebo by more than an acceptable margin. While the primary purpose of this study is to establish the safety profile of Cycloset in type 2 diabetes, any potential positive cardiovascular benefits will be evaluated as well. |
| NCT00441363 ↗ | Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin | Terminated | VeroScience | Phase 3 | 2005-02-01 | The purpose of this study is to investigate the efficacy and safety of Cycloset® and placebo when added to metformin monotherapy (at least 1000 mg/day for 3 months prior to screening) in persons with type 2 diabetes mellitus who are not adequately controlled on metformin therapy alone. |
| NCT00649168 ↗ | Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2007-04-01 | The objective of this study was to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg bromocriptine mesylate capsules, following the administration of a 10 mg dose, under fed conditions. |
| NCT00650520 ↗ | Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets | Completed | Mylan Pharmaceuticals | Phase 1 | 2007-05-01 | The objective of this study is to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg bromocriptine mesylate tablets, following the administration of a 10 mg dose, under fed conditions. |
| NCT02078440 ↗ | Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects | Completed | VeroScience | Phase 1 | 2014-01-01 | The objective of this study is to evaluate the relative bioavailability, and the rate and extent of absorption of bromocriptine in male and female children and adolescent Type 2 Diabetes Mellitus patients, aged 10 to less than 18, under fed conditions. It is undetermined if the pharmacokinetic profile of bromocriptine-QR in type 2 diabetes children aged 10- to less than 18 years differs appreciably from that in healthy adults. Bromocriptine is extensively metabolized by the liver (namely CYP3A4). Studies in children have demonstrated little difference in clearance among children over 10 years of age compared to adults (Blanco et al, 2000). However, differences in blood volumes or other factors may impart differences that could affect the pharmacokinetic properties of bromocriptine-QR. Therefore, this study will assess the pharmacokinetics in children aged 10-to less than 18 years who have type 2 diabetes. After describing the profile of bromocriptine-quick release in this patient population, a follow on study will be conducted to evaluate its safety and efficacy in treating children and adolescents who have type 2 diabetes. The pharmacokinetic profile of bromocriptine will be determined following the administration of a single, weight-adjusted dose of CYCLOSET (bromocriptine mesylate) tablets. The study will be a single period, bioavailability study in 30 patients. The study duration will be 3 days. |
| NCT03384524 ↗ | Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME | Withdrawn | Case Western Reserve University | Phase 1/Phase 2 | 2018-03-01 | This phase I/II trial is designed to provide proof of concept evidence that combination therapy can have a beneficial effect on DME and possibly prevent increases in retinal volume or progression of non-central DME into the central subfield of the macula. If a beneficial effect is apparent in this phase I/II study involving a relatively small sample size and short follow-up period, its results could be used to in plan future phase III trials. We believe this study will be the first to show that a systems pharmacology approach can successfully address diabetic macular edema, and thus revolutionize the treatment of complex retinal diseases for which there are a paucity of effective treatment options. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BROMOCRIPTINE MESYLATE
Condition Name
Clinical Trial Locations for BROMOCRIPTINE MESYLATE
Trials by Country
Clinical Trial Progress for BROMOCRIPTINE MESYLATE
Clinical Trial Phase
Clinical Trial Sponsors for BROMOCRIPTINE MESYLATE
Sponsor Name
